|Articles|March 1, 2004

Pharmacy Times

  • Volume 0
  • 0

Lithium Carbonate ER

Roxane Laboratories Inc (Columbus,Ohio) recently announced the approval ofLithium Carbonate Extended ReleaseTablets USP, 450 mg. This product is ABratedto GlaxoSmithKline?s Eskalith CR(lithium carbonate) 450 mg. LithiumCarbonate Extended Release Tablets areindicated for the treatment of manicepisodes of manic?depressive illness.Maintenance therapy prevents or diminishesthe intensity of subsequentepisodes in those manic?depressivepatients with a history of mania. Thetablets may produce a normalization ofsymptomatology within 1 to 3 weeks. Formore information, visit www.roxane.com.

Articles in this issue

over 21 years ago

New Technologies Top Survey

over 21 years ago

PDX Software Gets High Marks

over 21 years ago

Seal•ON

over 21 years ago

SaltAire Sinus Relief

over 21 years ago

Zim's Crack Creme Hand Sanitizer

over 21 years ago

CoroWise Plant Sterols

over 21 years ago

Culturelle

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME